## Chemotherapy Protocol

## HAEMATOLOGY - HSCT ALLOGRAFT

## ALEMTUZUMAB-FLUDARABINE-MELPHALAN-METHOTREXATE (GvHD) <br> RELATED DONOR CONDITIONING

This regimen will only be available to prescribe at the Wessex Blood and Marrow Transplant Unit

## Regimen

- HSCT - Alemtuzumab-Fludarabine-Melphalan (Related Donor)-Methotrexate (GvHD)


## Indication

- Conditioning for reduced intensity haematopoeitic stem cell transplant (HSCT) with a related donor.


## Toxicity

| Drug | Adverse Effect |
| :--- | :--- |
| Alemtuzumab | Infusion-related reaction (fever, hypotension, chills, rashes), <br> allergic/anaphylactic reaction, aneamia, leucopenia, thrombocytopenia |
| Fludarabine | Vomiting, diarrhoea, nausea, fever, malaise |
| Melphalan | Nausea, vomiting, diarrhoea, stomatitis and alopecia. |
| Methotrexate | Headache, back or shoulder pain, fever, mucositis |

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

## Monitoring

## Drugs

- FBC, LFTs and U\&Es prior to initiating treatment
- GFR measurement done by Nuclear Medicine prior to first day of treatment
- LFTs and creatinine prior to methotrexate
- Evaluate mucositis prior to administration of methotrexate


## Dose Modifications

The dose modifications listed are for liver and renal function. Dose adjustments may be necessary for other co-morbidities which will involve discussions with the Transplant Director or senior Transplant Clinician.

## Haematological

Confirm with transplant consultant before proceeding if there are signs of disease relapse.

## Hepatic Impairment

No studies have been done in patients with hepatic dysfunction receiving alemtuzumab.
Dose adjustment is a clinical decision but is unlikely to require reduction.
No dose modification is recommended for hepatic dysfunction in those receiving fludarabine.
No information available is available on melphalan in hepatic impairment. No dose changes recommended.

| Serum Bilirubin level $\boldsymbol{\mu \mathrm { mol }} / \mathbf{L}$ | Methotrexate dose |
| :--- | :--- |
| less than or equal to 35 | $100 \%$ dose |
| $36-50$ | $50 \%$ dose |
| $51-85$ | $25 \%$ dose |
| greater than 85 | omit dose |

## Renal Impairment

| Drug | Creatinine Clearance ( $\mathrm{ml} / \mathrm{min}$ ) | Dose (\% of original dose) |
| :---: | :---: | :---: |
| Alemtuzumab | No studies have been conducted. No dose adjustment is recommended in renal impairment |  |
| Fludarabine | greater than $70 \mathrm{ml} / \mathrm{min}$ | 100\% |
|  | 30 to $70 \mathrm{ml} / \mathrm{min}$ | Adjust towards 50\% |
|  | less than $30 \mathrm{ml} / \mathrm{min}$ | contraindicated |
| Melphalan | greater than $50 \mathrm{ml} / \mathrm{min}$ | 100\% |
|  | $30-50 \mathrm{ml} / \mathrm{min}$ | 50\% |
|  | less than $30 \mathrm{ml} / \mathrm{min}$ | Not generally recommended |


| Serum Creatinine level $\mu \mathrm{mol} / \mathrm{L}$ | Methotrexate dose |
| :--- | :--- |
| less than or equal to145 | $100 \%$ dose |
| $146-165$ | $50 \%$ dose |
| $166-180$ | $25 \%$ dose |
| greater than 180 | omit dose |

## Other

Dose adjustments may be necessary for mucositis caused by the transplant conditioning schedule. If mucositis is $\mathrm{NCI}-\mathrm{CTC}$ grade 3 or more on day +11 the methotrexate dose may be reduced or omitted. This should be discussed with the patient's transplant clinician.

Regimen

| Drug | Dose | Days | Administration |
| :---: | :---: | :---: | :---: |
| Alemtuzumab | 10 mg | -7 | Intravenous infusion in 100 ml sodium chloride $0.9 \%$ over 6 to 8 hours |
|  | 20 mg | -6 |  |
| Fludarabine | $30 \mathrm{mg} / \mathrm{m}^{2}$ | -7, -6, -5, -4, -3 | Intravenous infusion in 50 ml sodium chloride $0.9 \%$ over 30 minutes |
| Melphalan | $140 \mathrm{mg} / \mathrm{m}^{2}$ | -2 | Intravenous infusion in 500 ml sodium chloride $0.9 \%$ over 30 minutes |
| GvHD Prophylaxis (ciclosporin prescribed separately on the in-patient prescribing system) |  |  |  |
| Methotrexate | $5 \mathrm{mg} / \mathrm{m}^{2}$ | +3, +6, +11 | Intravenous bolus over 5 minutes |

## Dose Information

- The melphalan dose is rounded to nearest 10 mg . The National Dose Banding Team have advised not to use dose banding tables for this product in view of the 90 minute expiry (must be made locally for individual patient), the 50 mg vial size and frequent stock shortages.
- Fludarabine doses are rounded to the nearest 2.5 mg (down if halfway).
- Methotrexate will be dose rounded to the nearest 2.5 mg (down if halfway). The most common doses are $5 \mathrm{mg}, 7.5 \mathrm{mg}, 10 \mathrm{mg}, 12.5 \mathrm{mg}$ and 15 mg . Doses will normally be supplied as two individual syringes containing different amounts to allow dose adjustment on the day of administration that may fall on a weekend.


## Administration Information

Extravasation

- Alemtuzumab - non-vesicant
- Fludarabine - non-vesicant
- Melphalan - non-vesicant
- Methotrexate - non-vesicant


## Other

- It is the responsibility of the nurse administering the dose to ensure that the patient's transplant clinician has checked the bilirubin, creatinine and mucositis of the patient and documented the dose to be administered before each methotrexate dose is given.

Additional Therapy

- Antiemetics

Prior to alemtuzumab, fludarabine and melphalan;

- metoclopramide 10 mg three times a day oral or intravenous
- ondansetron 8 mg twice a day oral or intravenous

Prior to melphalan

- aprepitant 125 mg once a day prior to melphalan followed by 80 mg once a day for the two days afterwards
- Prior to the administration of the alemtuzumb and stem cells
- chlorphenamine 10 mg intravenous
- paracetamol 1000mg oral

Pethidine $12.5 \mathrm{mg}-25 \mathrm{mg}$ intravenous can be administered under the supervision of a doctor for the treatment of alemtuzumab induced rigors.

- Antimicrobials should be prescribed according to the individual transplant schedule and may include;
- gut decontamination
- antifungal according to consultant preference
- antivirals
- antibacterials
- Intravenous hydration before and after melphalan infusion prescribed on inpatient prescribing system (instruction) and using paper proforma (appendix 1)

The evening before melphalan infusion (to be completed by 0930 on the morning of the infusion)
sodium chloride $0.9 \%$ with potassium chloride 27 mmol 1000 ml
The day of melphalan infusion
0900hrs Start fluid chart and daily weights. Contact pharmacy to make melphalan infusion for delivery to ward at 1045hrs

0930hrs 1000 ml sodium chloride $0.9 \%$ intravenous infusion over 90 minutes
1010hrs 20 mg furosemide intravenous bolus
1045hrs Measure urine output since 0900hrs

- if more than 500 ml continue with melphalan infusion
- if less than 500 ml give furosemide 20 mg intravenous, check urine output since 0900hrs again at 1100hrs:
- if more than 500 ml go ahead with melphalan
- if less than 500 ml contact the prescriber.

1100hrs - give melphalan intravenous infusion over thirty minutes (this product has a short expiry so adhering to set timing is essential)

1130hrs - 1000 ml sodium chloride $0.9 \%$ intravenous infusion over 120 minutes
1330hrs - 1000ml sodium chloride $0.9 \%$ with potassium chloride 27 mmol intravenous infusion over 240 minutes

1730hrs - 1000ml sodium chloride $0.9 \%$ intravenous infusion over 360 minutes
2330hrs - 1000ml sodium chloride $0.9 \%$ with potassium chloride 27 mmol intravenous infusion over 480 minutes

The day after melphalan infusion
0730hrs - 1000ml sodium chloride $0.9 \%$ intravenous infusion over 480 minutes then restart routine intravenous fluids

- Mouthwashes including;
- nystatin 1 ml four times a day
- sodium chloride $0.9 \% 10 \mathrm{ml}$ four times a day
- Graft versus host disease (GvHD) prophylaxis is prescribed in accordance with the individual transplant schedule
- ciclosporin oral or intravenous
- methotrexate intravenous bolus on days $+3,+6$ and +11 (on ARIA)
- Calcium folinate 30 mg ( $15 \mathrm{mg} / \mathrm{m}^{2}$ is the precise dose but in practice 30 mg is given) intravenous bolus given six hourly for four doses starting 24 hours after each methotrexate bolus $(+4,+7,+12)$


## Coding

- Procurement - 71.5
- Delivery - Inpatient regimen

[^0]
## REGIMEN SUMMARY

Alemtuzumab-Fludarabine-Melphalan (Related Donor)-Methotrexate (GvHD)

Other than those listed below, supportive medication for this regimen will not appear in ARIA as prescribed agents. The administration instructions for each warning describes the agents that must be prescribed on the in-patient chart or general electronic prescribing system.

## Day -7

1. Warning - Check supportive medication prescribed

Administration instructions
Please refer to the individual transplant schedule for full details of the required supportive medlcines

1. Antibacterials, including gut decontamination, in accordance with the individual transplant schedule
2. Antifungals in accordance with the individual transplant schedule
3. Antivirals in accordance with the individual transplant schedule
4. Metoclopramide 10 mg three times a day oral or intravenous
5. Ondansetron 8 mg twice a day oral or intravenous
6. Aprepitant 125 mg once a day on the day of melphalan administration followed by 80 mg once a day for two days afterwards
7. Nystatin mouthwash 1 ml four times a day
8. Sodium chloride $0.9 \%$ mouthwash 10 ml four times a day
9. Ciclosporin in accordance with the individual transplant schedule
10. Calcium folinate 30 mg intravenous bolus six hourly for four doses on days $+4,+7,+12$
11. Chlorphenamine 10 mg intravenous when required as a premedication for alemtuzumab
12. Paracetamol 1000 mg oral when required as a premedcation for alemtuzumab
13. Pethidine $12.5-25 \mathrm{mg}$ intravenous when required for alemtuzumab rigors
14. Furosemide 20 mg four times a day when required for the treatment of fluid overload oral or intravenous
15. Melphalan hydration as per paper chart
16. Gastric protection
17. Heparin line lock in accordance with Trust central venous access device management procedure
18. Reminders for chemotherapy administration including methotrexate, calcium folinate and stem cells
19. Chlophenamine 10 mg intravenous

Administration Instructions
Administer 30 minutes prior to the alemtuzumab. Check in-patient prescribing system to ensure it has not been administered
3. Paracetamol 1000 mg oral

Administration Instructions
Administer 30 minutes prior to the alemtuzumab. Check in-patient prescribing system to ensure it has not been administered. Maximum dose is 4000 mg per 24 hours
4. Fludarabine $30 \mathrm{mg} / \mathrm{m}^{2}$ intravenous infusion in 50 ml sodium chloride $0.9 \%$ over 30 minutes
5. Alemtuzumab 10 mg intravenous infusion in 100 ml sodium chloride $0.9 \%$ over 6 hours.
Administration Instructions
Alemtuzumab should be started 30 minutes after a premedication of chlorphenamine 10 mg intravenous and paracetamol 1000mg oral

If rigors occur the infusion should be slowed, alemtuzumab may be administered over 8 hours. Administer pethidine $12.5-25 \mathrm{mg}$ intravenous under the supervision of a doctor

## Day -6

## 6. Chlophenamine 10 mg intravenous

Administration Instructions
Administer 30 minutes prior to the alemtuzumab. Check in-patient prescribing system to ensure it has not been administered
7. Paracetamol 1000 mg oral

Administration Instructions
Administer 30 minutes prior to the alemtuzumab. Check in-patient prescribing system to ensure it has not been administered. Maximum dose is 4000 mg per 24 hours
8. Fludarabine $30 \mathrm{mg} / \mathrm{m}^{2}$ intravenous infusion in 50 ml sodium chloride $0.9 \%$ over 30 minutes
9. Alemtuzumab 20 mg intravenous infusion in 100 ml sodium chloride $0.9 \%$ over 6 hours.
Administration Instructions
Alemtuzumab should be started 30 minutes after a premedication of chlorphenamine 10 mg intravenous and paracetamol 1000mg oral

If rigors occur the infusion should be slowed, alemtuzumab may be administered over 8 hours. Administer pethidine $12.5-25 \mathrm{mg}$ intravenous under the supervision of a doctor

## Day - 5

10. Fludarabine $30 \mathrm{mg} / \mathrm{m}^{2}$ intravenous infusion in 50 ml sodium chloride $0.9 \%$ over 30 minutes

## Day - 4

11. Fludarabine $30 \mathrm{mg} / \mathrm{m}^{2}$ intravenous infusion in 50 ml sodium chloride $0.9 \%$ over 30 minutes

## Day -3

12. Fludarabine $30 \mathrm{mg} / \mathrm{m}^{2}$ intravenous infusion in 50 ml sodium chloride $0.9 \%$ over 30 minutes

Day - 2
13. Warning - Check hydration and fluid balance

Administration Instructions
See separate hydration prescription chart for the pre hydration (Appendix 1):

1. Overnight to be completed at 0930 hrs on day of melphalan infusion, 1000 ml sodium chloride $0.9 \%$ with potassium chloride 27 mmol intravenous infusion The day of melphalan infusion:
2. 0900 hrs on the day of melphalan start fluid chart and daily weights. Contact pharmacy to make melphalan infusion for delivery to ward at 1045hrs
3. 0930 hrs 1000 ml sodium chloride $0.9 \%$ intravenous infusion over 90 minutes
4. 1010 hrs 20 mg furosemide intravenous bolus
5. 1045hrs Measure urine output since 0900hrs If more than 500 ml continue with melphalan infusion If less than 500 ml give second furosemide 20 mg dose intravenous bolus and recheck urine output since 0900 hrs again at 1100 hrs :

- if more than 500 ml go ahead with melphalan
- if less than 500 ml contact prescriber.

14. Time-Administer melphalan at 1100
15. Melphalan $140 \mathrm{mg} \mathrm{mg} / \mathrm{m}^{2}$ intravenous infusion in 500 ml sodium chloride $0.9 \%$ over 30 minutes

Administration Instructions - see separate hydration prescription chart for the post hydration (Appendix 1 of protocol)

1. 1100 hrs - give melphalan intravenous infusion over thirty minutes
2. $1130 \mathrm{hrs}-1000 \mathrm{ml}$ sodium chloride $0.9 \%$ intravenous infusion over two hours
3. $1330 \mathrm{hrs}-1000 \mathrm{ml}$ sodium chloride $0.9 \%$ with potassium chloride 27 mmol intravenous infusion over four hours
4. $1730 \mathrm{hrs}-1000 \mathrm{ml}$ sodium chloride $0.9 \%$ intravenous infusion over six hours
5. $2330 \mathrm{hrs}-1000 \mathrm{ml}$ sodium chloride $0.9 \%$ with potassium chloride 27 mmol intravenous infusion over eight hours
6. The day after melphalan infusion: $0730 \mathrm{hrs}-1000 \mathrm{ml}$ sodium chloride $0.9 \%$ intravenous infusion over eight hours and then restart routine intravenous fluids

## Day +3, +6, +11

## 16. Warning - Check calcium folinate prescribed

Administration instructions
Ensure that calcium folinate is prescribed on the inpatient prescribing system. Prescribe 30 mg intravenous bolus every 6 hours for 4 doses starting 24hours after the methotrexate, at 1700hrs, 2300hrs, 0500hrs, 1100 hrs (days +4 , $+7,+12$ )

## 17. Time - Administer methotrexate at 1700

Administration Instructions
Administer the methotrexate at 1700
18. Methotrexate $5 \mathrm{mg} / \mathrm{m}^{2}$ intravenous bolus over 5 minutes

Administration Instructions
Administer at 1700
Check the patient's notes to confirm the dose to be prescribed
It is the responsibility of the nurse administering the dose to ensure that the patient's transplant clinician has checked the bilirubin, creatinine and mucositis of the patient and documented the dose to be given before each methotrexate dose is administered.

Methotrexate will be dose rounded to the nearest 2.5 mg (down if halfway). The most common doses are $5 \mathrm{mg}, 7.5 \mathrm{mg}$, $10 \mathrm{mg}, 12.5 \mathrm{mg}$ and 15 mg . Doses will normally be supplied as two individual syringes containing different amounts to allow dose adjustment on the day of administration that may fall on a weekend.

DOCUMENT CONTROL

| Version | Date | Amendment | Written By | Approved By |
| :---: | :---: | :---: | :---: | :---: |
| 1 | Aug 2017 | None | Harriet Launders <br> Pharmacist <br> Dr Deborah Wright <br> Pharmacist | Dr Deborah Richardson <br> Consultant <br> Haematologist |
| Dr Kate Hill <br> Specialist Haematologist |  |  |  |  |

This chemotherapy protocol has been developed as part of the chemotherapy electronic prescribing project. This was and remains a collaborative project that originated from the former CSCCN. These documents have been approved on behalf of the following Trusts;

University Hospital Southampton NHS Foundation Trust
All actions have been taken to ensure these protocols are correct. However, no responsibility can be taken for errors that occur as a result of following these guidelines.


## NHS

```
Unit no (affix hospital addressograph)
```

Appendix 1: WESSEX BLOOD AND
Surname
First name
Date of Birth
Ward
MARROW TRANSPLANT -HYDRATION

WARD
PRESCRIPTION FOR HIGH DOSE
MELPHALAN CHEMOTHERAPY
CONDITIONING FOR HSCT
Consultant

| DAY | DATE \& TIME | DRUG | DOSE | INFUSION FLUID \& VOLUME | ADDITIVES | ROUTE | INFUSION RATE | $\begin{gathered} \text { GIVEN/ } \\ \text { CHECKED } \end{gathered}$ | START/ STOP | COMMENTS |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| If urine output greater than 500 ml since 0900 hrs continue with melphalan <br> MELPHALAN - See ARIA prescription <br> If urine output less than 250 ml since 0900 hrs (despite two doses of furosemide 20 mg iv) contact prescriber first |  |  |  |  |  |  |  |  |  |  |
|  | 1130 | HYDRATION FLUID | 1000 ml | Sodium chloride 0.9\% 1000 ml |  | IV | Infuse over 2 hours at $500 \mathrm{ml} / \mathrm{hr}$ |  |  |  |
|  | 1330 | HYDRATION FLUID | 1000ml | Sodium chloride 0.9\% Potassium chloride 0.2\% ( 27 mmol ) 1000 ml |  | IV | Infuse over 4 hours at $250 \mathrm{ml} / \mathrm{hr}$ |  |  |  |
|  | 1730 | HYDRATION FLUID | 1000 ml | Sodium chloride 0.9\% 1000 ml |  | IV | Infuse over 6 hours at $166 \mathrm{ml} / \mathrm{hr}$ |  |  |  |
|  | 2330 | HYDRATION FLUID | 1000 ml | Sodium chloride 0.9\%, Potassium chloride 0.2\% (27mmol) 1000 ml |  | IV | Infuse over 8 hours at $125 \mathrm{ml} / \mathrm{hr}$ |  |  |  |
|  | 0730 | HYDRATION FLUID | 1000 ml | Sodium chloride 0.9\% 1000 ml |  | IV | Infuse over 8 hours at $125 \mathrm{ml} / \mathrm{hr}$ |  |  |  |
| Prescribed by : |  | Date: |  |  |  | Pharmacist: |  | Date: |  |  |


[^0]:    References

    1. P-P-54 Wessex Blood and Marrow Transplant - Dose adjustments for stem cell transplant conditioning agents policy. Version 1.0
    2. P-P-20 Wessex Blood and Marrow Transplant - Reduced toxicity conditioning regimens policy Version 1.2
    3. Dosage Adjustments for Cytotoxics in Hepatic Impairment January 2009 University College London Hospitals
    4. Summary of Product Characteristics for Alemtuzumab (Lemtrada) - last updated 28 Jun 2016
    5. Summary of Product Characteristics for Fludarabine (Sandoz) - last updated 16 Jul 2015
    6. Summary of Product Characteristics for Melphalan (Aspen) - last updated 09 Dec 2014
    7. Handbook of Systemic Treatments for Cancer $7^{\text {th }}$ Edition 2012 Lilly Oncology
    8. National Dose Banding Tables
